ALL. B

Decreto Rettore Università di Roma "La Sapienza" n. 2173/2020 del 27/08/2020

CATERINA SCUDERI
Curriculum Vitae

Rome
September 11, 2020

Part I – General Information

Full Name	CATERINA SCUDERI
Languages	ITALIAN: native – ENGLISH fluent (speaking, reading, writing) – SPANISH: intermediate (speaking, reading, writing)

Part II – Education

Type	Year	Institution	Notes (Degree, Experience, …)
University graduation	2004	University of Palermo	Master's Degree in Medicinal Chemistry (Chimica e Tecnologia Farmaceutiche) *magna cum laude*. Experimental thesis in pharmacology title "Effect of sigma receptors modulation on ethanol self-administration in alcohol preferring rats".
PhD	2008	University of Palermo	PhD in Pharmacology and Toxicology. Thesis title: "The role of reactive gliosis in the pathophysiology of Alzheimer's disease: a possible target for cannabinoids?"
Licensure	2004	University of Palermo	Board-Certified Pharmacist
Post-graduate education	2007	Second University of Naples and the Italian Society of Pharmacology	Course in "Clinical trials of drugs, role of ethics committees and adverse reactions to drugs"
International PhD program in Neuropharmacology. Summer School	2009	University of Catania	Summer School of Neuroscience "Drug tolerance and addiction: from preclinical models to clinical management"
International PhD program. Summer School	2010	Université Lille Nord de France, Lille	Summer School of Neuroscience "Early Programming of Adult Modern Diseases"

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
01/11/2014	present	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine, Department of Physiology and Pharmacology	Assistant Professor with tenure
01/03/2014	31/10/2014	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Post-Doc Research Fellow. Research project title “Ruolo della glia nei processi neuroinfiammatori”
01/05/2013	31/01/2014	University of Manchester - Faculty of Biology, Medicine and Health	Visiting Scientist. Research project titled “Astroglial remodelling in neurological diseases”
01/03/2012	28/02/2014	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Post-Doc Research Fellow. Research project title “Ricerca e Sviluppo di bioregolatori attivi sui meccanismi epigenetici dei processi infiammatori nelle malattie croniche e degenerative (BIAM-EPI)”
01/03/2011	28/02/2012	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Post-Doc Research Fellow. Research project title “Interazioni anabolizzanti/cannabinoidi: studi neurochimici e comportamentali nel ratto”
01/03/2010	28/02/2011	University "G. D’Annunzio" of Chieti-Pescara - School of Medicine, Department of Biomedical Sciences.	Post-Doc Research Fellow. Research project title “Ruolo del sistema endocannabinoide nelle patologie neurodegenerative”
01/06/2009	31/12/2009	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Continuous and coordinated research term-contract. Research project title “Ruolo del sistema endocannabinoide in modelli animali di neurodegenerazione con particolare riferimento al morbo di Alzheimer”
01/06/2008	31/05/2009	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Post-Doc Research Fellow. Research project title “Sistema endocannabinoide e malattia di Alzheimer: studi in vitro e in vivo sui possibili effetti operati dai cannabinomimetici e dalle ALIAmidi sui processi neuroinfiammatori / neurodegenerativi indotti dal peptide beta amiloide”
01/06/2006	31/12/2007	SAPIENZA University of Rome - Department of Physiology and Pharmacology	Scientific Guest (research activities carried out within the PhD program)

IIIB – Other Appointments

Start	End	Institution	Position
06/11/2018	06/11/2024	Italian Ministry of Education, University and Research (MIUR)	National Scientific Qualification to Full Professor in Pharmacology (Abilitazione Scientifica Nazionale per Professore I fascia SSD BIO/14 SSC 05/G1)
12/04/2017	12/04/2023	Italian Ministry of Education, University and Research (MIUR)	National Scientific Qualification to Associate Professor in Pharmacology (Abilitazione Scientifica Nazionale per Professore II fascia SSD BIO/14 SSC 05/G1)
2017	present	Italian Ministry of Education, University and Research (MIUR)	Member of REPRISE (albo degli esperti scientifici istituito presso il MIUR) for the section Basic research
2018	2023	SAPIENZA University of Rome - Interdepartmental collaborative project between the Department of Physiology and Pharmacology and the Department of Chemistry and Technologies of Drugs	Project coordinator
2018	present	SAPIENZA University of Rome - Department of Chemistry and Technologies of Drugs - Second level specializing Master in “I manager chiave nell’azienda nutraceutica e cosmeceutica”	Member of the Scientific Committee
June 2019	present	SAPIENZA University of Rome- Faculty of Pharmacy and Medicine - Residency in Clinical Pharmacology and Toxicology	Member of the Residency Program Committee
March 2019	present	SAPIENZA University of Rome - Department of Physiology and Pharmacology - International PhD Program in Pharmacology and Toxicology	Member of the PhD Program Committee
18/12/2018	present	SAPIENZA University of Rome – Faculty of Pharmacy and Medicine – Bachelor’s Degree in Applied Pharmaceutical Sciences	President of the AQ Management Committee (Review Group)
12/10/2015	present	SAPIENZA University of Rome – Department of Chemistry and Technologies of Drugs - Residency in Hospital Pharmacy	Member of the Organizing Board of the Residency program

2014	present	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine	Thesis mentor to master's degree students (Pharmacy, Medicinal Chemistry, and Biotechnology) and to Bachelor's Degree students (Applied Pharmaceutical Sciences)
2013	present	SAPIENZA University of Rome - Department of Chemistry and Technologies of Drugs - Residency in Hospital Pharmacy	Member of the Residency Program Committee
01/01/2018	31/12/2018	Enrico and Enrica Sovena Foundation	Tutor and research fellowship coordinator for the research project titled "Study of the role of glia in the maladaptive response to stress as a possible pharmacological target in psychiatric disorders"
2016/2017		SAPIENZA University of Rome - Department of Chemistry and Technologies of Drugs - Residency in Hospital Pharmacy	Member of the Committee for admission to the Residency in Hospital Pharmacy
2018/2019		SAPIENZA University of Rome - Department of Chemistry and Technologies of Drugs - Residency in Hospital Pharmacy	Secretary of the Committee for admission to the Residency in Hospital Pharmacy
27/10/2015	17/12/2018	SAPIENZA University of Rome – Faculty of Pharmacy and Medicine – Bachelor's Degree in Applied Pharmaceutical Sciences	Member of the AQ Management Committee (Review Group)
01/11/2013	14/02/2017	SAPIENZA University of Rome - Department of Physiology and Pharmacology - PhD program of Pharmacology and Toxicology	Thesis co-supervisor for the European PhD Program
01/01/2010	31/10/2014	Epitech Group SpA pharmaceutical company (Saccolongo - PD, Italy)	Consultant as Pharmacologist
2009	2014	SAPIENZA University of Rome	Thesis co-mentor to master's degree students (Pharmacy, Genetics and Molecular Biology, Basic and Biomedical Research).
2016	present	SAPIENZA University of Rome	Thesis supervisor for the PhD Program in Pharmacology and Toxicology

Part IV – Teaching experience

The teaching activity have been carried out in the Institutional Courses of the former Faculty of Pharmacy and of the current Faculty of Pharmacy and Medicine at SAPIENZA, University of Rome.
All activities have been combined with several tasks such as thesis supervisor and mentor to both Bachelor's and Master's Degrees students. Currently, I am a member of the Graduate Committee for conferring the Master's Degree in Pharmacy and in Medicinal Chemistry as well as the Bachelor's Degree in Applied Pharmaceutical Sciences, and President of the examination committee for the following exams:

Course	Sector	Cfu	Graduate Course of Study
FARMACOLOGIA	BIO/14	9.0	14455-SCIENZE FARMACEUTICHE APPLICATE [L-270 - Ordin. 2010] - L-29 FARMACIA E MEDICINA
FARMACOLOGIA	BIO/14	9.0	16071-SCIENZE FARMACEUTICHE APPLICATE [L-270 - Ordin. 2012] - L-29 FARMACIA E MEDICINA
FARMACOLOGIA	BIO/14	5.0	00554-SCIENZE E TECNOLOGIA DEI PRODOTTI ERBORISTICI [L-509 - Ordin. 2002 - Interateneo con L'Università degli Studi della Tuscia] - sede di CIVITAVECCHIA - 24 FARMACIA E MEDICINA
FARMACOLOGIA APPLICATA E FITOVIGILANZA	BIO/14	6.0	16071-SCIENZE FARMACEUTICHE APPLICATE [L-270 - Ordin. 2012] - L-29 FARMACIA E MEDICINA
FARMACOLOGIA E FARMACOTERAPIA	BIO/14	10.0	00584-INFORMAZIONE SCIENTIFICA SUL FARMACO [L-509 - Ordin. 2002] - 24 FARMACIA E MEDICINA
FARMACOLOGIA GENERALE E FARMACOTERAPIA	BIO/14	12.0	28678-SCIENZE FARMACEUTICHE APPLICATE [L-270 - Ordin. 2017] - L-29 FARMACIA E MEDICINA
FARMACOLOGIA SPERIMENTALE	BIO/14	6.0	28678-SCIENZE FARMACEUTICHE APPLICATE [L-270 - Ordin. 2017] - L-29 FARMACIA E MEDICINA
METODOL.FARMACOLOGICHE E FARMACOGNOSTICHE	BIO/14	5.0	00554-SCIENZE E TECNOLOGIA DEI PRODOTTI ERBORISTICI [L-509 - Ordin. 2002 - Interateneo con L'Università degli Studi della Tuscia] - sede di CIVITAVECCHIA - 24 FARMACIA E MEDICINA
TOSSICOLOGIA	BIO/14	10.0	11156-FARMACIA U.E. [LSCU - Ordin. 2006] - 14/S FARMACIA E MEDICINA
TOSSICOLOGIA	BIO/14	12.0	14444-FARMACIA [LMCU - Ordin. 2010] - LM-13 FARMACIA E MEDICINA
TOSSICOLOGIA	BIO/14	12.0	27630-FARMACIA [LMCU - Ordin. 2015] - LM-13 FARMACIA E MEDICINA
TOSSICOLOGIA	BIO/14	5.0	00554-SCIENZE E TECNOLOGIA DEI PRODOTTI ERBORISTICI [L-509 - Ordin. 2002 - Interateneo con L'Università degli Studi della Tuscia] - sede di CIVITAVECCHIA - 24 FARMACIA E MEDICINA
TOSSICOLOGIA	BIO/14	5.0	00584-INFORMAZIONE SCIENTIFICA SUL FARMACO [L-509 - Ordin. 2002] - 24 FARMACIA E MEDICINA

Academic courses as appointed Professor

Year	Institution	Course
2018/2019 - present	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine - Master's Degree in Pharmacy.	Tossicologia (12 CFU)
2018/2019 - present	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine - Bachelor's Degree in Applied Pharmaceutical Sciences.	Farmacologia Sperimentale (6 CFU)
2017/2018	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine - Bachelor's Degree in Applied Pharmaceutical Sciences.	Farmacologia e Farmacoterapia (12 CFU)
2016/2017-present	SAPIENZA University of Rome. Department of Physiology and Pharmacology - Ph.D. Program in Pharmacology and Toxicology.	Farmacologia Cellulare e Molecolare (1 CFU)
2015/2016 and 2016/2017	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine - Bachelor's Degree in Applied Pharmaceutical Sciences.	Tossicologia (6 CFU)
2015/2016 and 2016/2017	SAPIENZA University of Rome- Faculty of Pharmacy and Medicine - Bachelor's Degree in Applied Pharmaceutical Sciences.	Farmacologia (9 CFU)
2015/2016 and 2016/2017	SAPIENZA University of Rome - Faculty of Pharmacy and Medicine - Bachelor's Degree in Applied Pharmaceutical Sciences.	Farmacologia Applicata e Fitovigilanza (6 CFU)
2013/2014-present	SAPIENZA University of Rome - Department of Chemistry and Technologies of Drugs - Residency Program in Hospital Pharmacy.	Farmacoterapia basata sull'evidenze (2 CFU)
2013/2014 and 2015/2016	SAPIENZA University of Rome - Department of Physiology and Pharmacology - Ph.D. Program in Pharmacology and Toxicology.	Farmacologia Clinica e and Farmacovigilanza (1 CFU)

Modules in Academic courses

2009/2010	SAPIENZA University of Rome – Faculty of Pharmacy - Master's Degree in Pharmacy.	Module (10 hours) on "Farmacologia generale e farmacocinetica, interazioni farmacologiche e reazioni avverse a farmaci e sostanze naturali" within the course of Farmacologia e Farmacoterapia
2009/2010	SAPIENZA University of Rome – Faculty of Pharmacy - Master's Degree in Medicinal Chemistry.	Module (6 hours) on "Principi e metodologie in farmacovigilanza di agenti terapeutici naturali, di sintesi, biotecnologici e biologici". within the course of Sperimentazione Clinica, Farmacoepidemiologia e Farmacovigilanza
2008/2009	SAPIENZA University of Rome – Faculty of Pharmacy - Master's Degree in Pharmacy.	Module (8 hours) on "Farmacologia Generale" within the course of Farmacologia e Farmacoterapia

Part V - Society memberships, Fellowships, Travel grants and Awards

Year	Title
2015	Member, Mediterranean Neuroscience Society (MNS).
2014	Award for the best research in Pharmacology of the Central Nervous System (SIF-Otsuka Pharmaceutical).
2011	Travel grant to attend the 14th Congress of the European Shock Society. Giardini Naxos (ME), Italy.
2010	Travel grant to attend the WORLDPHARMA2010, 16th World Congress of Basic and Clinical Pharmacology Copenhagen, Denmark.
2010	Travel grant to attend the Summer School “Early Programming of Adult Modern Diseases”. Lille (France) of the International PhD program -Université of Lille Nord de France.
2010	Member, European Shock Society (ESS).
2009	Member, American Society for Neuroscience (SfN).
2009	Travel grant to attend the VII Summer School of Neuroscience “Drug tolerance and addiction: from preclinical models to clinical management” of the International PhD program in Neuropharmacology - University of Catania.
2008	Member, Italian Society of Pharmacology (SIF).
2005	Individual 3-year PhD fellowship (Fondo per il sostegno dei giovani, Ex D.M. n. 198/2003).

Part VI - Funding Information [grants as Principal Investigator or Investigator]

Year	Title	Program	Grant value
2019	Studio delle basi molecolari del binge eating disorder per l'identificazione di nuovi target farmacologici: focus sulla neuroglia"	SAPIENZA University of Rome: Progetti di Ricerca di Università 2019 prot. RM11916B7A8D0225 - **Principal Investigator**	€ 10740
2019	Studio degli effetti di palmitoiletanolamide (PEA)/Luteolina co-ultramicronizzata e PEA-Oxazolina co-ultramicronizzata sulla modulazione della funzionalità gliale, la neuroinfiammazione e i processi neurodegenerativi in modelli preclinici di malattia di Alzheimer	Epitech Group Spa – Research Contract – **Principal Investigator**	€ 30500
2019	Studying multiple cellular endpoints by a Cell Imaging Multi-Mode Reader: a unique and affordable instrument for multi-mode detection, live-cell analysis and both high-contrast brightfield and fluorescence imaging	SAPIENZA University of Rome: Progetti di Ricerca di Università 2019 -Acquisizione di medie e grandi attrezzature scientifiche prot. MA31916B88EA2B5C - **Investigator**	€ 75000
2018	Enhancing strength and generalization of extinction memory to treat posttraumatic stress disorder (PTSD): a preclinical study focusing on the interplay between the glucocorticoid and endocannabinoid systems	SAPIENZA University of Rome: Progetti di Ricerca di Università 2018 prot. RG11816431C76A51 - **Investigator**	€ 27000
2016	Discovering molecular mechanisms of glia dysfunction in Alzheimer's disease	SAPIENZA University of Rome: Progetti di Ricerca di Università 2016 -Acquisizione di medie e grandi attrezzature scientifiche prot. n.MA116154CD981DAE - **Principal Investigator**	€ 36000
2015	Le basi neurobiologiche del consumo compulsivo di cibo: ricerca di nuovi approcci terapeutici	Italian Ministry of Education, Universities and Research (MIUR): PRIN 2015 prot. 2015KP7T2Y_002- **research unit Principal Investigator**	€ 42526
2015	Astrocyte dysfunction and neurodegeneration: evidence from a transgenic mouse model of Alzheimer's disease	SAPIENZA University of Rome: Progetti di Ricerca di Università 2015 prot. C26A15X58E - **Principal Investigator**	€ 4000

2012	Nuovi target farmacologici per il trattamento del dolore cronico: coinvolgimento del sistema immuno-infiammatorio periferico e centrale	Italian Ministry of Education, Universities and Research (MIUR): PRIN 2012 prot. 2012WBSSY4_006- **Investigator**	€ 175714
2012	La modulazione dell'astrogliosi come possibile nuova terapia della malattia di Alzheimer: studio degli effetti della palmitoiletanolamide in un modello transgenico di malattia	SAPIENZA University of Rome: Progetti di Ricerca di Università 2012 prot. C26A12EZK7- **Investigator**	€ 12000
2011	Involvement of hypothalamic-brainstem circuits in the satiety-inducing effects of oleoylethanolamide"	SAPIENZA University of Rome: Progetti di Ricerca di Università 2011 prot. C26A11WXBF- **Investigator**	€ 40000
2009	La palmitoietanolamide può rappresentare un approccio innovativo per il trattamento della malattia di Alzheimer? Studio delle proprietà anti-infiammatorie e neuroprotettive della palmitoiletanolamide in un modello murino transgenico di Alzheimer.	Italian Ministry of Education, Universities and Research (MIUR): PRIN 2009 prot. 2009NKZCNX – **Investigator**	€ 105976
2009	Interazioni anabolizzanti/cannabinoidi: studi neurochimici e comportamentali nel ratto	Italian Ministry of Health: Program of research on drugs, substances and medical practices that can be used for the purpose of doping in sport 2009 prot. 2009-2 – **Investigator**	€ 150000
2007	Ricerca e Sviluppo di bioregolatori attivi sui meccanismi epigenetici dei processi infiammatori nelle malattie croniche e degenerative (BIAM-EPI)	Italian Ministry of Education, Universities and Research (MIUR): PON 2007-2013 prot. PON01_02512 – **Investigator**	€ 261000
2005	Ricerca e Sviluppo del Farmaco (CHEM-PROFARMA-NET). Sintesi, caratterizzazione biologica e farmacologica di nuove molecole organiche, bioorganiche e naturali ad attività antidegenerativa (neuro o cardiovascolare), immunomodulatrice, antivirale ed anti-infettiva	Italian Ministry of Education, Universities and Research (MIUR): FIRB PIATTAFORME-RETI 2005 prot. RBPR05NWWC_012– **Investigator**	€ 228154

Part VII – Research Activities

Keywords	Brief Description
Neuropharmacology Alzheimer's disease Neuroglia Neuropsychiatric disorders Palmitoylethanolamide Endocannabinoid system Natural and Synthetic cannabinoids Cannabidiol Autism spectrum disorder Eating disorders	My research activities have always been centered in the field of neuropharmacology. My interest revolves around characterizing the importance of glial cells in the pathogenesis of brain diseases with the translational aim to develop novel therapeutic approaches.
	One of my lines of research focuses on evaluating the role of the endocannabinoid system in the pathogenesis of Alzheimer's disease, and on the possibility that natural and/or synthetic cannabinoids may represent innovative drugs in the treatment of this disorder.
	My studies were the first showing that interactions at cannabinoid CB1/CB2 receptors result in a dual regulation of beta-amyloid-induced reactive astrogliosis. Moreover, my data contributed to demonstrate that cannabidiol and palmitoylethanolamide, two natural cannabinoid-related compounds, through the interaction with the peroxisome proliferator-activated receptors modulate reactive gliosis (a phenomenon that contributes significantly to the neuronal damage occurring in neurodegenerative diseases) thus promoting neuronal survival. My results point towards the notion that cannabidiol and palmitoylethanolamide represent ideal candidates as therapeutic tools thanks to their high tolerability and safety profiles.
	Another line of research focuses on characterizing the molecular mechanisms underlying the onset and/or progression of Alzheimer's disease, with particular reference to the role played by glial cells, in order to identify possible targets for future treatments. By using different in vitro and in vivo models, I demonstrated the presence of important alterations of the cerebral homeostasis caused by glial abnormalities. Obtained results have contributed to clarify the possible consequences of astrocyte and microglia activation, demonstrating the presence of significant structural and functional modifications of these cells that are related to: (i) alterations of the cerebral cytoarchitecture, (ii) modifications of cerebral metabolism and (iii) neuronal death. My results support the hypothesis that the pharmacological manipulation of glial functionality may represent a promising and innovative therapeutic approach for neurodegenerative pathologies for which no treatments are currently available or not capable to delay the disease onset and/or slow down its course.
	I have also been interested in how aging affects morphology and functions of glial cells since aging represents one of the major risk factors for the development of several neurodegenerative pathologies. Preliminary results indicate that aging rather than pathology alters the function of these cells.
	Moreover, I am performing an in-depth molecular analysis of specific markers of astrocytes, oligodendrocytes, and microglial cells in an animal model of autism spectrum disorder. The results collected so far demonstrate that glial responses are heterogeneous and depend on the age examined and on the brain areas involved.
	New collaborative projects are ongoing on the involvement of glial cells in in vivo models of binge eating and acute stress.

NATIONAL AND INTERNATIONAL COLLABORATIONS

- Department of Pharmaceutical Health Care and Sciences, Kyushu University (Japan), Prof. Mami Noda.
- Faculty of Life Sciences, The University of Manchester (Manchester, UK), Prof. Alexei Verkhratsky.
- Beth Israel Deaconess Medical Center, Harvard Medical School (Boston, MA), Prof. Volney Sheen.
- Department of Sciences, University Roma Tre, Rome (Italy), Prof. Viviana Trezza.
- Department of Clinical and Experimental Medicine, University of Foggia, Foggia (Italy), Prof. Tommaso Cassano.
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara (Italy), Prof. Luca Ferraro.
- Department of Pharmacy (DIFAR), Section of Pharmacology and Toxicology, University of Genoa (Italy), Prof. Giambattista Bonanno.
- Department of Pharmaceutical Sciences, University of Milan (Italy), Prof. Maurizio Popoli.
- School of Pharmacy, University of Camerino, Camerino (Italy) Prof. Carlo Cifani.
- Department of Cell Biology and Neuroscience, Higher Institute of Health, Rome (Italy), Dr. Rossella Canese.
- Department of Science, Section of Biomedical Sciences and Technologies, University Roma Tre, Rome (Italy), Prof. Valentina Pallottini.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international, peer-reviewed]	40	SCOPUS	2006	2020
Chapters in Books [scientific]	3	SCOPUS	2018	2020
Chapters in Books [teaching]	1	Minerva Medica (https:///www.minervamedica.it/it/volumi/specialita-mediche/farmacologia/scheda.php?cod=L0285	2016	2019

Total Impact factor	146,725 (JCR-Journal Citation Report - Web of Science)
Average Impact factor per peer-reviewed paper (book chapters excluded)	3,668 (JCR-Journal Citation Report - Web of Science)
Impact factor last 10 years (2010-2020)	113,586 (JCR-Journal Citation Report - Web of Science)
Total Citations	1584 (Scopus)
Average Citations per peer-reviewed paper (book chapters excluded)	39,4 (Scopus)
Hirsch (H) index	22 (Scopus)
Normalized H index*	1,375 [22 / (2020-2004)]

*****H index divided by the academic seniority.

First, last, and/or **corresponding author** in the **51,16%** of **all** (40 papers and 3 indexed book chapters) **publications.**

First, last, and/or **corresponding author** in the **61,765%** of **the** (31 papers and 3 indexed book chapters) **publications published in the last 10 years.**

Part IX– Selected Publications

List of the publications selected for the evaluation

Citations from Scopus, Impact Factor from Journal Citation Report - JCR (Web of Science)

1. Facchinetti R, Valenza M, Bronzuoli MR, Menegoni G, Ratano P, Steardo L, Campolongo P, **Scuderi C*****. Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. Int J Mol Sci. 2020 May 27;21(11):3802. doi: 10.3390/ijms21113802. ***Corresponding author. Citations 0; Impact factor 4,556.**
2. Valenza M, Facchinetti R, Steardo L, **Scuderi C***. Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. Front Pharmacol. 2020 Jan 29; 10:1656. doi: 10.3389/fphar.2019.01656. ***Corresponding author. Citations 2; Impact factor 4,225.**
3. Romano A, Micioni Di Bonaventura MV, Gallelli CA, Koczwara JB, Smeets D, Giusepponi ME, De Ceglia M, Friuli M, Micioni Di Bonaventura E, **Scuderi C**, Vitalone A, Tramutola A, Altieri F, Lutz TA, Giudetti AM, Cassano T, Cifani C, Gaetani S. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder. Neuropsychopharmacology. 2020 Apr 30. doi: 10.1038/s41386-020-0686-z. **Citations 1; Impact factor 6,751.**
4. Bronzuoli MR, Facchinetti R, Valenza M, Cassano T, Steardo L, **Scuderi C***. Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. Front Pharmacol. 2019; 10:644. doi: 10.3389/fphar.2019.00644. ***Corresponding author. Citations 4; Impact factor 4,225.**
5. Bronzuoli MR, Facchinetti R, Ingrassia D, Sarvadio M, Schiavi S, Steardo L, Verkhratsky A, Trezza V, **Scuderi C***. Neuroglia in the autistic brain: evidence from a preclinical model. Mol Autism. 2018; 9:66. doi: 10.1186/s13229-018-0254-0. ***Corresponding author. Citations 9; Impact factor 5,712.**
6. **Scuderi C**, Bronzuoli MR, Facchinetti R, Pace L, Ferraro L, Broad KD, Serviddio G, Bellanti F, Palombelli G, Carpinelli G, Canese R, Gaetani S, Steardo L jr, Steardo L, Cassano T. Ultramicronized Palmitoylethanolamide Rescues Learning and Memory Impairments in a Triple Transgenic Mouse Model of Alzheimer's Disease by Exerting Anti-Inflammatory and Neuroprotective Effects. Transl Psychiatry. 2018; 8(1):32. doi: 10.1038/s41398-017-0076-4. **Citations 24; Impact factor 5,182.**
7. Bronzuoli MR, Facchinetti R, Luca Steardo L jr, Romano A, Stecca Claudia, Passarella S, Steardo L, Cassano T, **Scuderi C**. Palmitoylethanolamide dampens reactive astrogliosis and improves neuronal trophic support in a triple transgenic model of Alzheimer's disease: in vitro and in vivo evidence. Oxid Med Cell Longev. 2018; 2018:4720532. doi: 10.1155/2018/4720532. **Citations 15; Impact factor 4,868.**
8. **Scuderi C***, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, Steardo L, Pompili E, Fumagalli L, Campolongo P and Steardo L. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death and Disease 2014; 5: e1419. doi:10.1038/cddis.2014.376. ***Corresponding author. Citations 43; Impact factor 5,014.**
9. **Scuderi C**, Valenza M, Stecca C, Esposito G, Carratù MR and Steardo L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferatoractivated receptor-α. J Neuroinflammation 2012 Mar 9;9:49. doi: 10.1186/1742-2094-9-21. **Citations 84; Impact factor 4,351.**
10. Esposito G[§], **Scuderi C**[§], Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR, Iuvone T, Steardo L. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011; 6(12): e28668. doi: 10.1371/journal.pone.0028668. **§** ***Co-first authors***. **Citations 147; Impact factor 4,092.**
11. **Scuderi C**, Esposito G, Blasio A, Valenza M, Arietti P, Steardo jr L, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V and Steardo L. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med. 2011 Dec;15(12):2664-74. **Citations 66; Impact factor 4,125.**

12. Esposito G, Imitola J, Lu J, De Filippis D, **Scuderi C**, Ganesh VS, Folkerth R, Hecht J, Shin S, Iuvone T, Chesnut J, Steardo L, Sheen V. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet. 2008;17(3):440-57. **Citations 73; Impact factor 7,249.**

Total Impact factor of the 12 peer-reviewed publications	60,35 (JCR-Journal Citation Report - Web of Science)
Average Impact factor per peer-reviewed publication	5,029 (JCR-Journal Citation Report - Web of Science)
Total Citations of the 12 peer-reviewed publications	468 (Scopus)
Average Citations per peer-reviewed publication	39 (Scopus)

First, last, and/or **corresponding author** in the **83,33%** of the **12 publications selected for the evaluation.**

Part X – Scientific Achievements

PUBLICATIONS (Peer Reviewed Journals)

[The 12 publications selected for the evaluation are the number 1, 2, 3, 4, 7, 9, 10, 18, 26, 27, 30 and 36 are reported in the Part IX– Selected Publications].

Citations from Scopus, Impact Factor from Journal Citation Report - JCR (Web of Science)

1. Facchinetti R, Valenza M, Bronzuoli MR, Menegoni G, Ratano P, Steardo L, Campolongo P, **Scuderi C*****. Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. Int J Mol Sci. 2020 May 27;21(11):3802. doi: 10.3390/ijms21113802. ***Corresponding author. Citations 0; Impact factor 4,556.**
2. Valenza M, Facchinetti R, Steardo L, **Scuderi C***. Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. Front Pharmacol. 2020 Jan 29; 10:1656. doi: 10.3389/fphar.2019.01656. ***Corresponding author. Citations 2; Impact factor 4,225.**
3. Romano A, Micioni Di Bonaventura MV, Gallelli CA, Koczwara JB, Smeets D, Giusepponi ME, De Ceglia M, Friuli M, Micioni Di Bonaventura E, **Scuderi C**, Vitalone A, Tramutola A, Altieri F, Lutz TA, Giudetti AM, Cassano T, Cifani C, Gaetani S. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder. Neuropsychopharmacology. 2020 Apr 30. doi: 10.1038/s41386-020-0686-z. **Citations 1; Impact factor 6,751.**
4. Bronzuoli MR, Facchinetti R, Valenza M, Cassano T, Steardo L, **Scuderi C***. Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. Front Pharmacol. 2019; 10:644. doi: 10.3389/fphar.2019.00644. ***Corresponding author. Citations 4; Impact factor 4,225.**
5. Maftei D, Ratano P, Fusco I, Marconi V, Squillace S, Negri L, Severini C, Balboni G, Steardo L, Bronzuoli MR, **Scuderi C**, Campolongo P, Lattanzi R. The prokineticin receptor antagonist PC1 rescues memory impairment induced by β amyloid administration through the modulation of prokineticin system. Neuropharmacology. 2019; 158:107739. doi: 10.1016/j.neuropharm.2019.107739. **Citations 0; Impact factor 4,431.**
6. Cassano T, Magini A, Giovagnoli S, Polchi A, Calcagnini S, Pace L, Lavecchia MA, **Scuderi C**, Bronzuoli MR, Ruggeri L, Gentileschi MP, Romano A, Gaetani S, De Marco F, Emiliani C, Dolcetta D. Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. Exp Neurol. 2019; 311:88-105. doi: 10.1016/j.expneurol.2018. **Citations 7; Impact factor 4,691.**
7. Bronzuoli MR, Facchinetti R, Ingrassia D, Sarvadio M, Schiavi S, Steardo L, Verkhratsky A, Trezza V, **Scuderi C***. Neuroglia in the autistic brain: evidence from a preclinical model. Mol Autism. 2018; 9:66. doi: 10.1186/s13229-018-0254-0. ***Corresponding author. Citations 9; Impact factor 5,712.**
8. **Scuderi C***, Noda M, Verkhratsky A. Editorial: Neuroglia Molecular Mechanisms in Psychiatric Disorders. Front Mol Neurosci. 2018; 11:407. doi: 10.3389/fnmol.2018.00407. ***Corresponding author. Citations 3; Impact factor 3,72.**
9. **Scuderi C**, Bronzuoli MR, Facchinetti R, Pace L, Ferraro L, Broad KD, Serviddio G, Bellanti F, Palombelli G, Carpinelli G, Canese R, Gaetani S, Steardo L jr, Steardo L, Cassano T. Ultramicronized Palmitoylethanolamide Rescues Learning and Memory Impairments in a Triple Transgenic Mouse Model of Alzheimer's Disease by Exerting Anti-Inflammatory and Neuroprotective Effects. Transl Psychiatry. 2018; 8(1):32. doi: 10.1038/s41398-017-0076-4. **Citations 24; Impact factor 5,182.**
10. Bronzuoli MR, Facchinetti R, Luca Steardo L jr, Romano A, Stecca Claudia, Passarella S, Steardo L, Cassano T, **Scuderi C**. Palmitoylethanolamide dampens reactive astrogliosis and improves neuronal trophic support in a triple transgenic model of Alzheimer's disease: in vitro and in vivo evidence. Oxid Med Cell Longev. 2018; 2018:4720532. doi: 10.1155/2018/4720532. **Citations 15; Impact factor 4,868.**

11. Cartocci V, Catallo M, Tempestilli M, Segatto M, Pfrieger FW, Bronzuoli MR, **Scuderi C**, Servadio M, Trezza V, Pallottini V. Altered brain cholesterol/isoprenoid metabolism in a rat model of autism spectrum disorders. Neuroscience. 2018; 372:27-37. doi: 10.1016/j.neuroscience.2017.12.053. **Citations 16; Impact factor 3,244.**
12. Bronzuoli MR, Facchinetti R, Steardo L, **Scuderi C***. Astrocyte: an innovative approach for Alzheimer's disease therapy. Curr Pharm Des. 2017; 23(33):4979-4989. doi: 10.2174/1381612823666170710163411. ***Corresponding author. Citations 9; Impact factor 2,757.**
13. Bronzuoli MR, Iacomino A, Steardo L and **Scuderi C***. Targeting neuroinflammation in Alzheimer's disease. J Inflamm Res. 2016; 9:199-208. ***Corresponding author. Citations 87; Impact factor n/a.**
14. Steardo L Jr, Signorile A, **Scuderi C**, Carratù MR. How could retinoids fit into Alzheimer's therapy? Drugs Fut 2016; 41(1): 15 doi: 10.1358/dof.2016.041.01.2401820. **Citations 2; Impact factor 0,035.**
15. Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, **Scuderi C***. Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. Front Neurosci. 2015; 9:259. doi: 10.3389/fnins.2015.00259. ***Corresponding author. Citations 56; Impact factor 3,398.**
16. Cipriano M, Esposito G, Negro L, Capoccia E, Sarnelli G, **Scuderi C**, de Filippis D, Steardo L, Iuvone T. Palmitoylethanolamide regulates production of pro-angiogenic mediators in a model of β amyloid-induced astrogliosis in vitro. 2015; 14(7):828-37. **Citations 14; Impact factor 2,188.**
17. Capoccia E, Cirillo C, Marchetto A, Tiberi S, Sawikr Y, Pesce M, D'Alessandro A, **Scuderi C**, Sarnelli G, Cuomo R, Steardo L, Esposito G. S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncol Lett. 2015; 9(6):2864-2870. **Citations 14; Impact factor 1,482.**
18. **Scuderi C***, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, Steardo L, Pompili E, Fumagalli L, Campolongo P and Steardo L. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death and Disease 2014; 5: e1419. doi:10.1038/cddis.2014.376. ***Corresponding author. Citations 43; Impact factor 5,014.**
19. **Scuderi C**, Stecca C, Bronzuoli MR, Rotili D, Valente S, Mai A, Steardo L. Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. Front Pharmacol. 2014; 5:89. doi: 10.3389/fphar.2014.00089. **Citations 36; Impact factor 3,802.**
20. **Scuderi C***, Steardo L, Esposito G. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement. Phytother Res. 2014; 28(7):1007-13. doi: 10.1002/ptr.5095. ***Corresponding author. Citations 44; Impact factor 2,66.**
21. **Scuderi C**, Stecca C and Steardo L. Astrocyte role in major neurological disorders: the evidence and implications. IUBMB Life. 2013; 65(12):957-61. doi: 10.1002/iub.1223. **Citations 24; Impact factor 2,755.**
22. **Scuderi C** and Steardo L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol Disord Drug Targets. 2013; 12(1):62-9. **Citations 35; Impact factor 2,702.**
23. Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, **Scuderi C**, Steardo A, Cuomo R, Steardo L. Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytother Res. 2013; 27(5):633-6. doi: 10.1002/ptr.4781. **Citations 48; Impact factor 2,397.**
24. Esposito G, Capoccia E, Sarnelli G, **Scuderi C**, Cirillo C, Cuomo R, Steardo L. The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice. J Neuroinflammation. 2012; 9:277. doi: 10.1186/1742-2094-9-277. **Citations 18; Impact factor 4,351.**
25. Carratù MR, Marasco C, Signorile A, **Scuderi C**, Steardo L. Are Retinoids a Promise for Alzheimer's Disease Management? Curr Med Chem. 2012; 19(36):6119-25. **Citations 8; Impact factor 4,07.**

26. **Scuderi C**, Valenza M, Stecca C, Esposito G, Carratù MR and Steardo L. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator activated receptor-α. J Neuroinflammation 2012; 9:49. doi: 10.1186/1742-2094-9-21. **Citations 84; Impact factor 4,351.**

27. Esposito G[§], **Scuderi C**[§], Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR, Iuvone T, Steardo L. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011; 6(12): e28668. doi: 10.1371/journal.pone.0028668. **§** ***Co-first authors***. **Citations 147; Impact factor 4,092.**

28. De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, **Scuderi C**, Sarnelli G, Cuomo R, Steardo L, De Man JG, Iuvone T Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One. 2011; 6(12): e28159. doi: 10.1371/journal.pone.0028159. **Citations 71; Impact factor 4,092.**

29. Lu J, Esposito G, **Scuderi C**, Steardo L, Delli-Bovi LC, Hecht JL, Dickinson BC, Chang CJ, Mori T, Sheen V. S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors. PLoS One. 2011; 6(7): e22126. doi: 10.1371/journal.pone.0022126. **Citations 48; Impact factor 4,092.**

30. **Scuderi C**, Esposito G, Blasio A, Valenza M, Arietti P, Steardo jr L, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V and Steardo L. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med. 2011; 15(12):2664-74. doi: 10.1111/j.1582-4934.2011.01267.x. **Citations 66; Impact factor 4,125.**

31. De Filippis D, Cipriano M, Esposito G, **Scuderi C**, Steardo L, Iuvone T. Are anti-angiogenic drugs useful in neurodegenerative disorders? CNS Neurol Disord Drug Targets. 2010; 9(6):807-12. **Citations 5; Impact factor 3,618.**

32. De Filippis D, Steardo A, D'Amico A, **Scuderi C**, Cipriano M, Esposito G and Iuvone T. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection. ScientificWorldJournal. 2009; 9:229-35. doi: 10.1100/tsw.2009.31. **Citations 8; Impact factor 1,658.**

33. Iuvone T, Esposito G, De Filippis D, **Scuderi C** and Steardo L. Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neurosci Ther. 2009; 15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x. **Citations 115; Impact factor 2,69.**

34. **Scuderi C**, De Filippis D, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009; 23(5):597-602. doi: 10.1002/ptr.2625. **Citations 85; Impact factor 1,746.**

35. Esposito G, **Scuderi C**, Lu J, Savani C, De Filippis D, Iuvone T, Steardo L Jr, Sheen V, Steardo L. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med. 2008; 12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x. **Citations 65; Impact factor 5,114.**

36. Esposito G, Imitola J, Lu J, De Filippis D, **Scuderi C**, Ganesh VS, Folkerth R, Hecht J, Shin S, Iuvone T, Chesnut J, Steardo L, Sheen V. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet. 2008; 17(3):440-57. **Citations 73; Impact factor 7,249.**

37. Iuvone T, Esposito G, De Filippis D, Bisogno T, Petrosino S, **Scuderi C**, Di Marzo V, Steardo L. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. J Mol Med (Berl). 2007; 85(12):1379-92. **Citations 35; Impact factor 4,82.**

38. Esposito G, **Scuderi C**, Savani C, Steardo L Jr, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol. 2007; 151(8):1272-9. **Citations 143; Impact factor 3,767.**

39. Esposito G, Iuvone T, Savani C, **Scuderi C**, De Filippis D, Papa M, Di Marzo V, Steardo L. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther. 2007; 322(3):1144-52. **Citations 55; Impact factor 4,003.**
40. Esposito G, De Filippis D, Steardo L, **Scuderi C**, Savani C, Cuomo V, Iuvone T. CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett. 2006; 404(3):342-6. **Citations 57; Impact factor 2,092.**

BOOK CHAPTERS

1. **Scuderi C***, Verkhratsky A. The role of neuroglia in autism spectrum disorders. Progress in Molecular Biology and Translational Science 2020; 173:301-330. doi: 10.1016/bs.pmbts.2020.04.011. PubMed PMID: 32711814. ***Corresponding author. Citations 0; Impact factor 4,074.**
2. Facchinetti R, Bronzuoli MR, **Scuderi C***. An Animal Model of Alzheimer Disease Based on the Intrahippocampal Injection of Amyloid β-Peptide (1-42). Methods Mol Biol. 2018; 1727:343-352. doi: 10.1007/978-1-4939-7571-6_25. PubMed PMID:29222793**. *Corresponding author. Citations 8, Impact factor n/a.**
3. Bronzuoli MR, Facchinetti R, **Scuderi C***. Preparation of Rat Hippocampal Organotypic Cultures and Application to Study Amyloid β-Peptide Toxicity. Methods Mol Biol. 2018; 1727:333-341. doi: 10.1007/978-1-4939-7571-6_24. PubMed PMID:29222792. ***Corresponding author. Citations 0, Impact factor n/a.**
4. **Scuderi C**, Carratù MR, Racagni M, Cuomo V. "Anestetici locali" in F. Rossi – V. Cuomo – C. Riccardi. Farmacologia. Principi di base e applicazioni terapeutiche. Edizioni Minerva Medica SpA Torino, Italy (III and IV edition).

INVITED LECTURES

1. **Scuderi C**. What differentiates an aged astrocyte from an Alzheimer one? XV European Meeting on Glial Cells in Health and Disease, Marseille, France, July 7-10, 2021.
2. **Scuderi C**. Unraveling the complex glial response in aging and Alzheimer's disease. 40° Congress of the Italian Society of Pharmacology (SIF). Rome, March 9-13, 2021.
3. **Scuderi C**. Neuroinflammation in Alzheimer's disease: friend or foe? AAA Annual Meeting, held in conjunction with Experimental Biology, EB 2020, in San Diego (CA), April 4-7, 2020 (online due to COVID-19).
4. **Scuderi C**. Searching for a therapy: new hints from preclinical research to treat neurodegeneration. Giornata sulla "Valutazione delle funzioni neurocognitive e del disturbo depressivo del Paziente Anziano. Epitech Group informative day for Neurologists, Geriatrics, and Psychiatrists. Naples, October 8, 2019.
5. **Scuderi C.** Il ruolo della neuroinfiammazione nel declino cognitivo. I Congresso Nazionale S.I.Me.Ge.N. – Differenze di Genere nel Parkinson e nelle Demenze, Palermo, April 11-12, 2019.
6. **Scuderi C.** Quale futuro per la terapia delle malattie neurodegenerative: nuove evidenze dalla ricerca preclinica. Congresso della Società Italiana di Medicina di Genere nelle Neuroscienze "Donne in Neuroscienze, Neuromodulazione e Neuroplasticità': principi e potenziale". Bergamo, September 22, 2018.
7. **Scuderi C.** Glia and Alzheimer's disease: the pharmacological manipulation as promising tool against pathology progression. Convegno monotematico della Società di Farmacologia (SIF) - "Glial cells and therapeutic perspectives: from maladaptive plasticity to neurorestoration" Florence, June 29, 2018.
8. **Scuderi C.** Glial dysfunction in the pathogenesis of neuropsychiatric disorders: beyond inflammation, toward the development of novel therapies. Symposium "Overfeeding, dysmetabolism, inflammation and stress exposure as prominent actors in the drama of neuropsychiatric disorders: new insights for the development of novel therapies" 37° Congresso Nazionale della Società di Farmacologia (SIF). Naples, October 27-30, 2015.
9. **Scuderi C.** Il ruolo della glia nella patogenesi della neurodegenerazione: gli astrociti come nuovo target terapeutico. II Convegno update su sclerosi multipla e disturbi urologici. Matera, September 27, 2014.
10. **Scuderi C.** Is the modulation of reactive astrocytes a promising strategy for neurodegenerative diseases? Convegno "Disturbi cognitivi, dell'umore e comportamentali dai disturbi pervasivi alle demenze – Fondamenti eziopatogenetici e Terapie". Acerenza (PZ), September 26, 2014.
11. **Scuderi C**, Stecca C., Bronzuoli MR, Iacomino A, Steardo L. Neuron-astrocyte interplay in neurodegenerative disorders: evidence and implications. Convegno monotematico della Società Italiana di Farmacologia (SIF) "Looking Inside Neurons for a better Pharmacological Intervention: The Contribution of Imaging to the Study of Neurodegenerative Diseases". Catania, June 20, 2014.
12. **Scuderi C.** Il ruolo della glia nella patogenesi della neurodegenerazione: gli astrociti come nuovo target terapeutico. XI Corso di Aggiornamento in Neuroscienze. Catania, May 29-30, 2014.
13. **Scuderi C.** Neuroinflammation and Neurodegeneration: evidence and implications. III Congresso sulla Medicina di Genere: focus su malattie neurologiche declinate al femminile. Matera, May 16-17, 2014.
14. **Scuderi C.** Il ruolo delle cellule non neuronali nella patogenesi della neurodegenerazione: gli astrociti come nuovo target terapeutico. III Giornate Psicogeriatriche Agrigentine. Agrigento, December 5-7, 2013.

15. **Scuderi C.** Is the modulation of reactive astrocytes a promising strategy for AD therapy? Preclinical experience with palmitoylethanolamide. Simposio "New research on neurodegeneration: time to translate it to clinic?" 36° Congresso della Società Italiana di Farmacologia (SIF). Turin, October 23-26, 2013.
16. **Scuderi C**, Stecca C, Valenza M, Tita C, Esposito G, Steardo L. Cannabinoids and PPARs: new tools for Alzheimer's disease treatment. Convegno monotematico della Società Italiana di Farmacologia (SIF) "Cannabinoidi: presente e futuro". Ferrara, September 14-15, 2012.
17. **Scuderi C**, Valenza M, Ratano P, Pompili E, Fumagalli L, Esposito G, Campolongo P, Steardo L. Palmitoylethanolamide counteracts reactive gliosis in an in vivo model of Alzheimer's disease. Convegno monotematico della Società Italiana di Farmacologia (SIF) "I Cannabinoidi: dalla biologia alla clinica". Cagliari, September 29-30, 2011.

I have also presented more than 50 abstracts at national and international conferences.

EDITORIAL ACTIVITIES

- 2008 – present
  Reviewer for the following indexed journals: Molecular Autism, Cerebral Cortex, Neurobiology of Aging, Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology, Brain Research, Neuroreport, Neuroscience Letters, Neurotoxicity Research, Acta Physiologica, Journal of Neuroinflammation.
- Jul 2020 – present
  Associate Editor for Frontiers in Pharmacology, section Neuropharmacology
- Feb 2019 – present
  Review Editor for Frontiers in Pharmacology, section of Experimental Pharmacology and Drug Discovery.
- Nov 2015 – present
  Review Editor for the section Neuropharmacology hosted in Frontiers in Neuroscience; Frontiers in Psychiatry; Frontiers in Neurology; Frontiers in Pharmacology
- Nov 2015 – present
  Guest Associate Editor for Frontiers in Molecular Neuroscience
- Nov 2016 – Nov 2018
  Guest Associate Editor for a Frontiers Research Topic titled "Neuroglia Molecular Mechanisms in Psychiatric Disorders" hosted in Frontiers in Molecular Neuroscience and Frontiers in Cellular Neuroscience
- Oct 2010 – Oct 2015
  Associate Editor for Bioinfo Publications Journals

Procedura valutativa di chiamata a Professore Universitario di II fascia, codice concorso 2020PAR020, Settore Concorsuale 05/G1, Settore Scientifico Disciplinare BIO/14, Dipartimento di Fisiologia e Farmacologia, Facoltà di Farmacia e Medicina. D.R. n. 2173/2020 del 27/08/2020.

SCIENTIFIC MEETING ORGANIZATION

- Symposium titled “Play in advance on neurodegenerative processes: toward a new knowledge of glial cells in gut-brain axis” 39° Congress of the Italian Society of Pharmacology (SIF). Florence, 20-23 November 2019.

- International workshop on Neurological and Psychiatric Disorders: from Neurobiology to Medicine. Primo convegno monotematico della Società Italiana di Farmacologia (SIF) 2010. Rome, 12 March 2010.

La sottoscritta è a conoscenza che, ai sensi dell’art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996.

Signature